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Despite vaccination, pertussis is still endemic in the Netherlands. A literature search was performed to verify what is known about the role of
Bordetella species in children with cystic fibrosis, with regard to the incidence of Bordetella infections, the involvement in pulmonary
exacerbations and the influence on chronic course.
Little is known about the frequency of Bordetella infections and the involvement of Bordetella species both in relation to the chronic course of
cystic fibrosis and to pulmonary exacerbations. Since it is difficult to detect Bordetella species in cultures and few sputum cultures investigated
have been obtained during an exacerbation, it is likely that the frequency of Bordetella species in CF patients is underestimated. Identification of
Bordetella species in these patients may have serious consequences for the treatment of exacerbations in CF.
Future research investigating the role of Bordetella species in cystic fibrosis should use specific techniques to detect Bordetella in cultures.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Bordetella; Pertussis
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Cystic fibrosis (CF) is the most common inherited
autosomal-recessive disease in the Caucasian population. CF
is caused by mutations in the cystic fibrosis transmembrane
regulator (CFTR) and primarily affects the respiratory tract and
gastro-intestinal system. The respiratory disease is characterized
by chronic airway inflammation with periodic exacerbations
due to respiratory tract infections, presenting as an increase of
productive and often paroxysmal cough and dyspnoea. These
pulmonary exacerbations seriously affect morbidity and
mortality of patients as they may deteriorate the lung function
[1,2].
It is well known that several bacterial species as well as
viruses are involved in both chronic infections and pulmonary
exacerbations in individuals with cystic fibrosis. Frequently
involved pathogens are Staphylococcus aureus, Pseudomonas
aeruginosa, Haemophilus influenzae and Burkholderia cepacia
complex [2]. Recently, an increasing number of other pathogens
have been reported in patients with CF such as Stenotrophomonas
maltophilia, non-tuberculous mycobacteria, MRSA, Ralstonia
pickettii, Alcaligenes xylosoxidans, Burkholderia gladioli and
Aspergillus fumigatus [2]. However the exact role of these
microorganisms in the course of CF lung disease has not been
completely established yet [2].
There have also been anecdotal reports on a possible role for
another microbe in these patients, namely Bordetella species
[2–7]. The most well known member of this family, B.
pertussis, causes whooping cough or pertussis. Despite
vaccination, the incidence of pertussis has been rising over
the past decennia [8]. Studies of whooping cough in chronic
pulmonary disease in children are scarce and have focussed
merely on asthma.
The objective of this literature review is to verify what is
known about the role of Bordetella species in children with
cystic fibrosis.
The following questions were investigated:• What is the incidence of Bordetella species infections in CF
patients?
• Are Bordetella species involved in pulmonary exacerbations
of CF?
• Do infections with Bordetella species influence the chronic
course of CF?2. Methods literature study
We identified studies searching PUBMED, EMBASE and
Cochrane Central Register of Controlled Trials (CENTRAL)
from inception through July 2010 using the following search
terms: (1) “whooping cough”, “bordetella” or “pertussis” (2)
“cystic fibrosis” or “mucoviscidosis”. Predefined inclusion
criteria were: 1) identification of Bordetella species in CF
patients; 3) language: English; 4) species: humans; 5) type of
article: clinical studies, case–control studies, or case reports.
Date of the most recent search of PUBMED: July 30th 2010.Three reviewers (AB, TW, BA) independently screened
titles and abstracts for eligibility. Every article, considered
useful by at least one of the authors, was included. Also
reference lists of all the included studies and review articles
were reviewed for additional studies. The abstracts of all these
studies were read to determine if they should be included.
3. Results
The search strategy yielded a total of 92 articles. PUBMED
identified 47 articles, Cochrane 14 and EMBASE 46 articles of
which 15 were corresponding to articles identified in
PUBMED. After independently screening the titles and
abstracts, seven publications (all retrievable from PUBMED),
met the inclusion criteria and were considered for further
review. Most important reasons for exclusion were: 1) no
involvement of Bordetella species, 2) not CF patients, 3) only
description of CFTR functioning, 4) only description of
pertussis toxin in cell lines and 5) only reference Bordetella
to differential diagnosis.
After reading the full articles, one case-report did not
contribute to any of our questions; therefore six publications
were included in this literature review.
Of these, three publications were case-reports of CF patients
in whom Bordetella species were involved (Ner 2003 [3],
Wallet 2002 [5], Funke 1996 [6]). Two articles evaluated
sputum cultures in CF patients for several bacterial species,
including Bordetella species (Spilker 2008 [4], Coenye 2002
[2]). One study examined the clinical impact of bacterial
infections, including Bordetella, on lung function (Olesen 2006
[9]). No clinical studies were found.
4. What is the incidence of Bordetella (pertussis) infections
in CF patients?
Four studies evaluated either sputum samples or blood
samples of CF patients for the presence of Bordetella species
(Table 1). Incidence is dependent on the reliability of tests used.
Direct and indirect diagnostics are available. The two direct
tests consist of culture and real time polymerase chain reaction
(PCR) [10]. Nasopharyngeal aspirates, nasopharyngeal swabs
or sputum samples are needed for these tests. The indirect tests
measure anti-pertussis toxin antibodies in oral fluid or sera
using enzyme-linked immunosorbent assays (ELISA) or
multiplex immunoassays [11].
Spilker et al. [4] used a combination of the two direct
diagnoses, bacterial genotyping and 16S rDNA sequencing
(PCR), to recognize Bordetella species in sputum cultures of
874 CF patients receiving care in 183 treatment centers. In these
patients, Bordetella species were found in 43 samples from 43
patients during a 6 year period. This results in a 5% positivity
rate at a time for all patients and means an annual incidence of
7/874 patients/year. Although not reported, the number of
samples will have been around 500–1000 per year, i.e., if all
samples have been investigated for Bordetella then the
percentage of positive cultures must have been around 1%.
Their analysis of the 43 sputum samples revealed B.
Table 1
Studies evaluating the presence of Bordetella species in CF patients.
Author # CF patients Age # sputum samples # Bordetella (%) Species
Spilker et al. [4] N=874 No age limitation. CF patients:
3–53 years old 25 (58%) aged
b18 years
Not known 43 cultures from 43 patients
(5%) during a 6 year period
B. bronchiseptica/parapertussis
B. hinzii, B. petrii, B. avium,
unidentified B. spp.
Olesen et al. [9] N=59 b16 years old 206 blood samples 5 patients (ages 4–13 years)
(7.6%/year)
B. pertussis
Ner et al. [3] N=532 0–18 years old Not known 2 lung transplant recipients with
CF (ages 10 and 15 years) (3%)
2 CF patients (ages 2 and 14 years)
(0.4%) during a 9 year period
B. bronchiseptica
Coenye et al. [2] N=47 Age not known 51 1 (2%), period not known B. hinzii
Number of (#), number of CF patients (N).
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four were B. petrii, three were B. avium, and eight were
unidentified Bordetella species. Importantly, bacterial cultures
were positive for Bordetella species in only 11 (25%) of these
43 patients. Others were originally misclassified but identified
correctly by genotyping. This suggests that the recovery of
Bordetella is influenced by the presence of other species that
overgrow Bordetella in culture, causing an underestimation of
the prevalence of Bordetella within the CF population if only
bacterial cultures are used.
Olesen et al. [9] retrieved serum of 59 CF patients every 2–
4 months for 13 months. These blood samples were analyzed
using ELISA for IgM and IgG antibodies against Mycoplasma
pneumonia, Chlamydia pneumoniae and Bordetella pertussis.
They found a M. pneumonia infection in 11 patients
(17.2%/year), C. pneumoniae infection in 5 (7.9%/year) and
B. pertussis in 5 patients (7.6%/year), who had a rise in
antibodies against B. pertussis that could not be explained by
vaccination.
Ner et al. [3] conducted a retrospective medical record
review at one children's hospital over a 9 year period and
reported all cases with documented B. bronchiseptica infection.
Data collected of 60 lung transplant recipients and 532 CF
patients showed a total of 4 patients with positive respiratory
cultures for B. bronchiseptica. The diagnosis was made using
culture of sputum samples, except for one case where
bronchoalveolar lavage was used. Out of the 60 patients who
received a lung transplant, 2 with a primary diagnosis of CF
(3%) had documented B. bronchiseptica infection and 2/532
other CF patients (0.4%) were positive.Table 2
The involvement of Bordetella species in pulmonary exacerbations.
Author # of exacerbations Clinical features Spirometry
Funke et al. [6] N=8 (in 1 patient) • ↑ Cough
• Occasional fever
• Exertional dyspnoea
Mild deterio
(percentages
Wallet et al. [5] N=3
And 2 episodes of
pneumonia (in 1 patient)
• ↑ Sputum
• Fever of 38 °C
• Dyspnoea
FEV-1 1.2 l
1.4 l 6 mont
15% decrea
Number of (#); number of CF patients (N); FEV-1, Forced Expiratory Volume in OCoenye et al. [2] describe the use of both biochemical and
microbiological techniques (including gel electrophoresis, PCR
and fatty acid analysis) to characterize bacterial isolates in 51
sputum cultures of 47 CF patients attending 16 different
treatment centers in the United States. These isolates carried
pathogens that had not previously been reported from CF
patients. One of these unusual species was B. hinzii, detected in
1 isolate.5. Are Bordetella species involved in pulmonary
exacerbations of CF?
None of the studies discuss B. pertussis as the etiological
agent of an exacerbation in patients with CF. Two case-reports
[5,6] describe pulmonary exacerbations in CF patients in which
other Bordetella species are involved (Table 2).
One case-report describes eight pulmonary exacerbations in
a 51-year old CF patient during a 3-year period. [6] In all
exacerbations, B. hinzii was isolated from sputum samples with
culture. In six out of these eight episodes S. aureus was cultured
in parallel in the sputum samples. However, B. hinzii was the
only bacterium detected during two pulmonary exacerbations.
Despite mild exertional dyspnoea, no deterioration in pulmo-
nary disease was seen during a follow up period of three years.
The other case-report describes three exacerbations and two
episodes of pneumonia in a 27-year-old female [5]. In all the
episodes S. aureus and B. bronchiseptica were isolated in the
sputum with culture and PCR. Her lung function significantly
decreased due to the infections.Species in sputum
samples
Progression of CF pulmonary
disease
ration
not known)
6×
S. aureus and B.hinzii,
2× B. hinzii
No radiologic changes in the lung,
mild exertional dyspnoea
iter, versus
hs earlier,
se from baseline
5× S. aureus and
B. bronchiseptica
FEV-1 decreased to 0.95 l versus
1.4 l 3 years earlier.
ne Second.
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chronic course of CF?
None of the studies specifically address the consequences of
a B. pertussis infection for the progression of CF pulmonary
disease. Three studies [5,6,9] discuss the effect of other
Bordetella infections on pulmonary function of CF patients
(Table 3).
In the study of Olesen et al. [9] the clinical impact of atypical
bacterial infections, including B. pertussis, on lung function in
CF patients was investigated, using spirometry or sRaw
measurement. The patients, aged b16 years at enrollment,
were followed for 12 months at regular clinic visits and the lung
function was tested at every visit. Out of 59 CF patients
analyzed, 5 had a significant increase in antibodies against B.
pertussis, reflecting a natural infection.
The specific effect of the B. pertussis infection on lung
function is not described in this study, but for all patients with
atypical bacterial infections, consisting of 21 patients of which 5
had a B. pertussis infection, FEV-1 was significantly decreased
compared to the rest of the year (mean 79% with and 82%
without infection, p=0.039). To study the more long-term
impact on lung function, they compared the maximum FEV-1
and FEF25–75 in the 4 months prior to and the 4 months
following the study period. No significant difference was found
between the change in FEV-1 for negative patients and positive
patients.
The two case-reports [5,6] report a mild deterioration in
spirometry results during the infection with B. hinzii, though the
infection did not affect the pulmonary function, measured over a
3 year period. Results of lung function tests are not reported, nor
is the frequency of measurements [6]. During the B.
bronchiseptica infection, the forced expiratory volume in 1 s
(FEV1) significantly decreased to 1.2 l. Compared to a FEV-1
of 1.4 l 6 months earlier, this is a 15% decrease of baseline.
After 2.5 years, her condition was stabilized. However, her
pulmonary function had significantly decreased to a FEV-1 of
0.95 l during this period [5]. In both case-reports, patients were
co-infected with S. aureus.7. Discussion and conclusions
Our search revealed only a small number of publications
specifically addressing our main objectives for this literature
study.Table 3
Effect of Bordetella infections on pulmonary function of CF patients.
Author Type of infection FEV-1 dur
Olesen et al. [9] Atypical bacterial infection (C. pneumoniae,
M. pneumoniae, B. pertussis) 5/21 being B. pertussis
Significant
Funke et al. [6] Infection with S. aureus and B. hinzii Mild deteri
Wallet et al. [5] Infection with S. aureus and B. bronchiseptica Significant
1.4 liter) (1
FEV-1, Forced Expiratory Volume in One Second.Little is known about the frequency of Bordetella infections
and the involvement of Bordetella species both in relation to
the chronic course of cystic fibrosis and to pulmonary
exacerbations.
The frequency with which Bordetella species are detected in
CF patients is low as it varies from 0.4% till 7.6%. However,
these numbers are based on small numbers of CF patients and
none of the articles discussed Dutch patients. Pertussis is still
endemic in the Netherlands with a higher incidence compared to
the years before the epidemic of 1996–1997 [12]. Annually,
4000 to 8000 cases of whooping cough are reported [8]. While
the incidence in children receiving the preschool booster
vaccination has sharply decreased, the incidence in adolescents
and adults on the other hand has increased [8,12]. This increase
in incidence in adults is seen in other countries as well [13],
though in most of these countries, unlike the Netherlands,
booster vaccination is introduced for the population [14]. The
frequency of Bordetella species within CF patients in the
Netherlands may well be higher, due to transmission from
adolescents and adults to children with CF.
It is interesting to see that not only the causative agents of
whooping cough in humans, B. pertussis and B. parapertussis,
are seen in CF patients, but also the pathogens primarily found
in animals. For instance, most of the time, B. bronchiseptica is
transmitted by domestic or wild animals [3] and B. hinzii and B.
avium are transmitted by poultry or birds [6,7].
In none of the publications nasopharyngeal aspirates or
swabs have been used as samples for culture or PCR, even
though this seems to be the most reliable method [10]. In most
studies sputum samples have been used for the diagnosis.
Sputum samples may contain Bordetella, but the sensitivity of
detecting Bordetella DNA in sputum still needs to be validated
[10]. As throat swabs have been found to be less suitable [15],
the studies used materials that probably contain less Bordetella
DNA than if nasopharyngeal samples had been used. This might
have led to underestimation of the incidence of B. pertussis.
Furthermore, the timing of the collection of samples has been
less favorable. Even though the publications describing case-
reports [3,5,6] expressed obtaining the sputum cultures during
exacerbations, the larger studies all collected sputum cultures
from CF patients without exacerbations [2,4,9].
Currently, Bordetella species are not included in the standard
procedures of evaluating CF sputum cultures during an
exacerbation [4]. In addition, even when included in the
evaluation, several studies have shown that the identification of
CF pathogens, including Bordetella species, is difficult [2,4].ing the period of infection Long-term effect on pulmonary function
decrease of FEV-1 (79% versus 82%) None
oration (percentages not known) No radiologic changes in the lung,
mild exertional dyspnoea
decrease of FEV-1 (1.2 liter versus
5% decrease from baseline)
FEV-1 decreased to 0.95 l versus
1.4 l 3 years earlier.
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an overgrowth of other CF-related pathogens [4]. The species
will only be detected in sputum cultures when specific
techniques are used, what makes misidentification of these
organisms common using the regular microbial identification
methods [2,4]. This results in an underestimation of the
prevalence of Bordetella species, also (and maybe especially
because of abundant microbial presence in the sputum) in CF
patients.
An etiological role of Bordetella species in pulmonary
exacerbations cannot be excluded, based on the two case-
reports describing exacerbations in CF patients. Although in 6
out of 8 exacerbations S. aureus was detected as well, in two
episodes B. hinzii was the only microbe detected, suggesting an
association with the exacerbation. Another association might be
suggested for B. bronchiseptica. The decline in pulmonary
function seen in this patient is unusual for patients with long-
term isolated S. aureus colonization [5].
In daily practice pediatricians notice that more and more
exacerbations are difficult to treat when the regular antibiotic
treatment for CF exacerbations is used.
This suggests involvement of other atypical pathogens in
these exacerbations. Specific techniques to detect Bordetella
species in sputum cultures could identify its role in CF
exacerbations. A comparable lack of clinical response to
antibiotics was seen for the therapies initially used in the case
reports mentioned above [5,6]. To enable physicians to start the
right treatment in exacerbations, correct identification of CF
pathogens is important.
Macrolide antibiotics are used more and more in the
maintenance treatment of CF patients [16]. These antibiotics
are mainly used in CF patients with chronic Pseudomonas
colonization and also for their anti-inflammatory effects. No
evidence of a pattern of emerging macrolide resistance has been
seen, but resistant isolates have been identified [17].
None of the articles specifically addressed the consequences
of a B. pertussis infection for the progression of CF pulmonary
disease. Three studies discussed the effect of other Bordetella
infections on pulmonary function of CF patients and showed
unequivocal results. Although during exacerbations (almost by
definition) lung function decrease is seen, long term conse-
quences appear to be mild if any.
Are there pathophysiological explanations for a possible
negative effect of Bordetella infection in CF patients? This
remains unclear, but several mechanisms could be involved.
These mechanisms are especially based on animal studies.
Robay et al. [18] showed that the normal increase in CFTR
activity in normal human lung epithelium cells, caused by a β3-
agonist is nullified by pre-treatment with pertussis toxin. This
indicates that Bordetella infections might further impair CFTR
function in CF patients, who already show loss in CFTR
function due to the mutation in the CFTR gene. This could
increase all known effects of CFTR dysfunction and make these
patients even more susceptible to bacterial infections.
Another mechanism of increased susceptibility for infections
with many pathogens could arise from reduced antimicrobial
activity of CF airway surface fluid (ASF) [19]. Yim et al. [19]showed that treatment of CF cell lines with vitamin D content,
increased cathelicidin content in ASF, which induced antimi-
crobial activity against B. bronchiseptica. This suggests that the
reduced antimicrobial activity of CF airway surface fluid,
combined with the vitamin D deficiency which is common in
CF patients [19], makes them even more susceptible for
microbial airway colonization with, e.g., B. bronchoseptica.
Could we learn something from studies in other respiratory
disease, e.g. asthma?
For asthmatics, most articles focus on the effect of previous
pertussis infection on the development of asthma and other
atopic disorders. Suffering from pertussis rather than having
pertussis antibodies seems to increase the risk of atopic
disorders such as asthma, eczema or hay fever [20–26].
In a murine model, it was demonstrated that B. pertussis
infections exacerbate allergic asthma [27]. In addition, adults
with stable asthma reported asthma symptoms more frequently
and had a decrease in lung function, when positive for B.
pertussis [28]. This indicates that Bordetella species might
exacerbate allergic asthma in humans, but has not yet been
reported. If one would specifically look for Bordetella species
in sputum cultures of patients with exacerbated chronic lung
disease, one might identify this microbe more often.
In conclusion, it remains unclear if there is a role for
Bordetella species in the chronic morbidity and/or acute
exacerbations of cystic fibrosis. However, there are no reasons
to suppose that the rising incidence of pertussis is restricted to
non-CF patients.
Since it is difficult to detect Bordetella species in cultures
and since few sputum cultures investigated have been obtained
during an exacerbation, it is likely that the frequency of
Bordetella species in CF patients is underestimated. Identifica-
tion of Bordetella species in these patients may have serious
consequences for the treatment of exacerbations in CF.
Therefore, a prospective study investigating the role of
Bordetella species in cystic fibrosis using specific techniques to
detect Bordetella in cultures should yield further information
about this possibly important aspect of CF lung disease. The
development of a Bordetella specific PCR could contribute to
quicker, better and more specific determination of this new,
known pathogen.
In the meantime, if clinicians are confronted with a sudden
change in cough in CF children, our advice is to perform culture
and/or PCR of nasopharyngeal aspirates in the first three weeks
after the beginning of the “new symptoms of cough” and to
follow up with serology after three weeks of cough. In addition
we recommend a pertussis vaccine booster for this population of
CF children at risk.References
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